Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PCI Biotech Holding ASA ( (DE:4QG) ) has shared an announcement.
PCI Biotech has announced its decision to discontinue the development of its PCL technology due to insufficient progress in achieving critical milestones, which has led to increased project risks and resource demands. As a result, the company is now prioritizing the evaluation of strategic options for its future, including potential sale, merger, or wind-down, amid concerns over its financial sustainability beyond Q4 2025.
More about PCI Biotech Holding ASA
PCI Biotech is a biopharmaceutical company that focuses on developing and commercializing new technologies and therapies through its photochemical technology platform, originating from research at the Oslo University Hospital. The platform was under development in two areas: Photochemical lysis (PCL) for enhancing yield and purity in viral vector manufacturing, and Photochemical internalisation (PCI) for unlocking potential in various modalities.
Average Trading Volume: 576,906
Current Market Cap: NOK16.54M
See more insights into 4QG stock on TipRanks’ Stock Analysis page.